1
|
Mishra R, Haldar S, Biondi S, Bhari VK, Singh G, Bhowmick NA. TGF-β controls stromal telomere length through epigenetic modifications. 3 Biotech 2022; 12:290. [PMID: 36276465 PMCID: PMC9512944 DOI: 10.1007/s13205-022-03346-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 09/01/2022] [Indexed: 11/01/2022] Open
Abstract
Telomere length is primarily controlled by the enzyme telomerase, but being chromatin structures, telomeres undergo epigenetic regulation for their maintenance and function. Altered telomere length among cancer cells combined with shorter telomere length in cancer-associated stromal cells, strongly implicated with progression to prostate cancer metastasis and cancer death and providing a novel target for therapeutics. Transforming growth factor-β (TGF-β) signaling pathways are well-recognized for their role in stromal-epithelial interactions responsible for prostate androgen responsiveness, promoting tumorigenesis. However, the underlying mechanism remains unclear. We sought to establish a role for TGF-β in the regulation of telomere length in mouse and human prostate fibroblast. Polymerase chain reaction (PCR)-based telomere length measuring methods are widely used due to their repeatability and reproducibility. Using real-time RT-PCR-based telomere length measuring method, we identified that TGF-beta regulates telomere length via increased expression of histone methyltransferase, Suv39h1, which in turn affected histone methylation levels at the telomeric ends. Moreover, treatment of DAPT and non-steroidal antiandrogen bicalutamide demonstrated that notch and androgen signaling co-operated with TGF-ß in regulating stromal telomere length. Telomere variation in tumor cells and non-tumor cells within the tumor microenvironment greatly facilitates the clinical assessment of prostate cancer; therefore, understanding stromal telomere length regulation mechanism will hold significant prospects for cancer treatment, diagnosis, and prognosis. Supplementary Information The online version contains supplementary material available at 10.1007/s13205-022-03346-5.
Collapse
Affiliation(s)
- Rajeev Mishra
- Department of Life Sciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kalyanpur, Kanpur, UP 208024 India
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA
| | - Subhash Haldar
- Department of Food and Nutrition, University of Gour Banga, Mokdumpur, West Bengal 732101 India
| | - Shea Biondi
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA
| | - Vikash Kumar Bhari
- Department of Biosciences, Manipal University Jaipur, Jaipur, Rajasthan 303007 India
| | - Gyanendra Singh
- Toxicology Department, ICMR-National Institute of Occupational Health, Ahmedabad, 380016 India
| | - Neil A Bhowmick
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA
- Department of Research, Greater Los Angeles Veterans Administration, Los Angeles, CA 90073 USA
| |
Collapse
|
2
|
Westaby D, Jimenez-Vacas JM, Padilha A, Varkaris A, Balk SP, de Bono JS, Sharp A. Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers (Basel) 2021; 14:51. [PMID: 35008216 PMCID: PMC8750516 DOI: 10.3390/cancers14010051] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 12/12/2021] [Accepted: 12/15/2021] [Indexed: 12/15/2022] Open
Abstract
Despite major improvements in the management of advanced prostate cancer over the last 20 years, the disease remains invariably fatal, and new effective therapies are required. The development of novel hormonal agents and taxane chemotherapy has improved outcomes, although primary and acquired resistance remains problematic. Inducing cancer cell death via apoptosis has long been an attractive goal in the treatment of cancer. Apoptosis, a form of regulated cell death, is a highly controlled process, split into two main pathways (intrinsic and extrinsic), and is stimulated by a multitude of factors, including cellular and genotoxic stress. Numerous therapeutic strategies targeting the intrinsic apoptosis pathway are in clinical development, and BH3 mimetics have shown promising efficacy for hematological malignancies. Utilizing these agents for solid malignancies has proved more challenging, though efforts are ongoing. Molecular characterization and the development of predictive biomarkers is likely to be critical for patient selection, by identifying tumors with a vulnerability in the intrinsic apoptosis pathway. This review provides an up-to-date overview of cell death and apoptosis, specifically focusing on the intrinsic pathway. It summarizes the latest approaches for targeting the intrinsic apoptosis pathway with BH3 mimetics and discusses how these strategies may be leveraged to treat prostate cancer.
Collapse
Affiliation(s)
- Daniel Westaby
- Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; (D.W.); (J.M.J.-V.); (A.P.) (J.S.d.B.)
- Prostate Cancer Targeted Therapy Group, The Royal Marsden Hospital, London SM2 5PT, UK
| | - Juan M. Jimenez-Vacas
- Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; (D.W.); (J.M.J.-V.); (A.P.) (J.S.d.B.)
| | - Ana Padilha
- Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; (D.W.); (J.M.J.-V.); (A.P.) (J.S.d.B.)
| | - Andreas Varkaris
- Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; (A.V.); (S.P.B.)
| | - Steven P. Balk
- Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; (A.V.); (S.P.B.)
| | - Johann S. de Bono
- Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; (D.W.); (J.M.J.-V.); (A.P.) (J.S.d.B.)
- Prostate Cancer Targeted Therapy Group, The Royal Marsden Hospital, London SM2 5PT, UK
| | - Adam Sharp
- Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; (D.W.); (J.M.J.-V.); (A.P.) (J.S.d.B.)
- Prostate Cancer Targeted Therapy Group, The Royal Marsden Hospital, London SM2 5PT, UK
| |
Collapse
|
3
|
Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. Cancer Lett 2021; 520:213-221. [PMID: 34343635 DOI: 10.1016/j.canlet.2021.07.045] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/17/2021] [Accepted: 07/28/2021] [Indexed: 12/24/2022]
Abstract
Cell death is a natural process in organismal development, homeostasis and response to disease or infection that eliminates unnecessary or potentially dangerous cells and acts as an innate barrier to oncogenesis. Inactivation of cell death is a key step in tumour development and also impedes effective response to cancer therapy. Precise execution of unwanted cells is achieved through regulated cell death processes including the intrinsic apoptotic pathway that is governed by the BCL-2 (B-cell lymphoma 2) protein family. There is compelling evidence that intrinsic apoptosis is defective in prostate cancer, particularly in metastatic and castration resistant advanced disease, currently a lethal diagnosis. New therapeutics have been developed to target pro-survival BCL-2 proteins (including BCL-2, BCL-XL and MCL-1) and show promise in reinstating apoptosis to destroy tumour cells in haematological cancers. Here we discuss perturbation of cell death in prostate cancer and how new therapeutics could improve treatment outcome in prostate cancer.
Collapse
|
4
|
Gambini L, Udompholkul P, Baggio C, Muralidharan A, Kenjić N, Assar Z, Perry JJP, Pellecchia M. Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1. J Med Chem 2021; 64:4903-4912. [PMID: 33797903 DOI: 10.1021/acs.jmedchem.1c00005] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Modulating disease-relevant protein-protein interactions (PPIs) using pharmacological tools is a critical step toward the design of novel therapeutic strategies. Over the years, however, targeting PPIs has proven a very challenging task owing to the large interfacial areas. Our recent efforts identified possible novel routes for the design of potent and selective inhibitors of PPIs using a structure-based design of covalent inhibitors targeting Lys residues. In this present study, we report on the design, synthesis, and characterizations of the first Lys-covalent BH3 peptide that has a remarkable affinity and selectivity for hMcl-1 over the closely related hBfl-1 protein. Our structural studies, aided by X-ray crystallography, provide atomic-level details of the inhibitor interactions that can be used to further translate these discoveries into novel generation, Lys-covalent pro-apoptotic agents.
Collapse
Affiliation(s)
- Luca Gambini
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Parima Udompholkul
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Carlo Baggio
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Aruljothi Muralidharan
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Nikola Kenjić
- Department of Biochemistry, College of Natural and Agricultural Sciences, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Zahra Assar
- Cayman Chemical, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, United States
| | - J Jefferson P Perry
- Department of Biochemistry, College of Natural and Agricultural Sciences, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| | - Maurizio Pellecchia
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States
| |
Collapse
|
5
|
Patel A, Shah H, Shah U, Bambharoliya T, Patel M, Panchal I, Parikh V, Nagani A, Patel H, Vaghasiya J, Solanki N, Patel S, Shah A, Parmar G. A Review on the Synthetic Approach of Marinopyrroles: A Natural Antitumor Agent from the Ocean. LETT ORG CHEM 2021. [DOI: 10.2174/1570178617999200718004012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Natural products play an important role in various drug discovery and development approaches.
They are known to be the rich resources for the identification of new chemical entities
(NCEs) intended to treat various diseases. Many drugs have been discovered and developed from natural
sources. Indeed, collaborative efforts involving biologists as well as organic, medicinal, and phytochemists
usually facilitate the identification of potent NCEs derived from natural sources. Over the past
20 years, more than 50% of NCEs have been derived either from marine sources or synthetic/
semisynthetic derivatives of natural products. Indeed, many drug molecules have been designed by
considering natural products as the starting scaffold. The first bis-pyrrole alkaloid derivative of
marinopyrroles was obtained from the marine-derived streptomycete species. In the laboratory, it can
be synthesized via Clauson-Kaas and Friedel-Crafts arylation as well as copper-mediated N-arylation
process under microwave irradiation. The marinopyrrole A (±)-28 was discovered to overcome resistance
against human cancer cells by antagonizing B-cell lymphoma extra-large (Bcl-xL) and induced
myeloid leukaemia cell (Mcl-1). In this review, we elaborated on various synthetic pathways of
marinopyrroles possessing anti-cancer potential, which could encourage researchers to discover promising
anti-tumor agents.
Collapse
Affiliation(s)
- Ashish Patel
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta. Petlad, Dist. Anand, Gujarat,India
| | - Hirak Shah
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat,India
| | - Umang Shah
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta. Petlad, Dist. Anand, Gujarat,India
| | | | - Mehul Patel
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta. Petlad, Dist. Anand, Gujarat,India
| | - Ishan Panchal
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat,India
| | - Vruti Parikh
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat,India
| | - Afzal Nagani
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat,India
| | - Harnisha Patel
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat,India
| | | | - Nilay Solanki
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta. Petlad, Dist. Anand, Gujarat,India
| | - Swayamprakash Patel
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Ta. Petlad, Dist. Anand, Gujarat,India
| | - Ashish Shah
- Department of Pharmacy, Sumandeep Vidhyapeeth, Vadodara, Gujarat,India
| | - Ghanshyam Parmar
- Department of Pharmacy, Sumandeep Vidhyapeeth, Vadodara, Gujarat,India
| |
Collapse
|
6
|
Design of novel coumarins as potent Mcl-1 inhibitors for cancer treatment guided by 3D-QSAR, molecular docking and molecular dynamics. INFORMATICS IN MEDICINE UNLOCKED 2021. [DOI: 10.1016/j.imu.2021.100765] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
7
|
D’Aguanno S, Del Bufalo D. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells 2020; 9:cells9051287. [PMID: 32455818 PMCID: PMC7291206 DOI: 10.3390/cells9051287] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 05/18/2020] [Accepted: 05/19/2020] [Indexed: 12/30/2022] Open
Abstract
The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in order to develop small molecules able to target anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1. The limitations of the first Bcl-2 family targeted drugs, regarding on-target and off-target toxicities, have been overcome with the development of venetoclax (ABT-199), the first BH3 mimetic inhibitor approved by the FDA. The purpose of this review is to discuss the state-of-the-art in the development of drugs targeting Bcl-2 anti-apoptotic proteins and to highlight the potential of their application as single agents or in combination for improving anti-cancer therapy, focusing in particular on solid tumors.
Collapse
|
8
|
Whitaker RH, Placzek WJ. MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation. Cell Death Dis 2020; 11:156. [PMID: 32111816 PMCID: PMC7048787 DOI: 10.1038/s41419-020-2351-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 02/11/2020] [Indexed: 12/20/2022]
Abstract
Commitment to cell cycle entry and cellular duplication is a tightly coordinated and regulated process. Once initiated, a series of multiple checkpoints ensure both accurate genomic replication and chromosomal separation. In the event of unsuccessful cell division, parallel pathways exist that induce the cell to undergo programmed cell death, or apoptosis. At the center of such stress-induced, intrinsic apoptotic regulation lies the BCL2 family of pro- and anti-apoptotic regulatory proteins. In a proliferative state the balance of pro- and anti-apoptotic signaling proteins would be expected to favor an excess population of anti-apoptotic members. While the anti-apoptotic BCL2 family member, MCL1, has been identified to oversee mitotic progression, direct communication between the BCL2 family and cell proliferation has not been observed. In this study, we demonstrate a direct protein–protein interaction between MCL1 and the G1/S checkpoint protein, P18INK4C. This interaction is mediated by a reverse BH3 (rBH3) motif located in P18INK4C’s C-terminal ankyrin repeat. MCL1 is further shown to decrease P18INK4C expression and thereby regulate cell cycle entry in a retinoblastoma (RB1)-dependent manner. Our findings establish a mechanism for translation independent and direct communication between the BCL2 family regulation of apoptosis and CDK4/6-RB regulation of early G1/S transition during cellular division/growth.
Collapse
Affiliation(s)
- Robert H Whitaker
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA
| | - William J Placzek
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
| |
Collapse
|
9
|
Li C, Song Y, Li P. MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma. Cell Tissue Res 2019; 379:625-633. [PMID: 31754782 DOI: 10.1007/s00441-019-03105-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 09/15/2019] [Indexed: 11/29/2022]
Abstract
This research was conducted to study the role of MCL1 in ovarian adenocarcinoma cell death and survival as well as chemosensitivity to sabutoclax. Both in vitro and in vivo assays including qRT-PCR, Western blot, CCK-8, caspase 3/7 activation, colony foci formation assay and xenograft assay were conducted. Except for the xenograft assay, the other experiments were conducted at the cellular level and they were carried out to assess cell activities such as viability, programmed death and proliferation. SKOV3 and OVCAR3 cell lines were used as the cell models for all experiments. It was proved that MCL1 was overexpressed in ovarian adenocarcinoma (tissues and cells) at RNA and protein levels. MCL1 knockdown was also discovered to suppress the viability and proliferation of ovarian adenocarcinoma cells in vivo and in vitro. Lastly, it was found that MCL1 knockdown significantly promoted ovarian carcinoma cell death and the sensitivity to sabutoclax. Thus, we concluded that MCL1 acted as a cancer facilitator in ovarian adenocarcinoma and it is also a suppressor of sabutoclax sensitivity.
Collapse
Affiliation(s)
- Cui Li
- Department of Gynaecology and Obstetrics, Yantai Affiliated Hospital, Binzhou Medical College, No. 717 Jinbu Street, Muping District, Yantai, 264100, Shandong, China.
| | - Yuchun Song
- Department of Gynaecology and Obstetrics, Yantai Affiliated Hospital, Binzhou Medical College, No. 717 Jinbu Street, Muping District, Yantai, 264100, Shandong, China
| | - Pan Li
- Department of Gynaecology and Obstetrics, Yantai Affiliated Hospital, Binzhou Medical College, No. 717 Jinbu Street, Muping District, Yantai, 264100, Shandong, China
| |
Collapse
|
10
|
Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents. Cells 2019; 8:cells8040346. [PMID: 31013740 PMCID: PMC6523793 DOI: 10.3390/cells8040346] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 03/28/2019] [Accepted: 04/09/2019] [Indexed: 02/03/2023] Open
Abstract
Chemotherapeutic targeting of microtubules has been the standard of care in treating a variety of malignancies for decades. During mitosis, increased microtubule dynamics are necessary for mitotic spindle formation and successful chromosomal segregation. Microtubule targeting agents (MTAs) disrupt the dynamics necessary for successful spindle assembly and trigger programmed cell death (apoptosis). As the critical regulators of apoptosis, anti-apoptotic BCL2 family members are often amplified during carcinogenesis that can result in MTA resistance. This review outlines how BCL2 family regulation is positioned within the context of MTA treatment and explores the potential of combination therapy of MTAs with emerging BCL2 family inhibitors.
Collapse
|
11
|
Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res 2019; 139:298-313. [DOI: 10.1016/j.phrs.2018.11.020] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 11/13/2018] [Accepted: 11/13/2018] [Indexed: 02/07/2023]
|
12
|
Abstract
Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy.
Collapse
Affiliation(s)
- Weiguo Xiang
- Department of Internal Medicine, University of Michigan Medical School,
| | - Chao-Yie Yang
- Department of Internal Medicine, University of Michigan Medical School,
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA,
| | - Longchuan Bai
- Department of Internal Medicine, University of Michigan Medical School,
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA,
| |
Collapse
|
13
|
Henriques AC, Ribeiro D, Pedrosa J, Sarmento B, Silva PMA, Bousbaa H. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer Lett 2018; 440-441:64-81. [PMID: 30312726 DOI: 10.1016/j.canlet.2018.10.005] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 09/12/2018] [Accepted: 10/02/2018] [Indexed: 12/11/2022]
Abstract
Current microtubule-targeting agents (MTAs) remain amongst the most important antimitotic drugs used against a broad range of malignancies. By perturbing spindle assembly, MTAs activate the spindle assembly checkpoint (SAC), which induces mitotic arrest and subsequent apoptosis. However, besides toxic side effects and resistance, mitotic slippage and failure in triggering apoptosis in various cancer cells are limiting factors of MTAs efficacy. Alternative strategies to target mitosis without affecting microtubules have, thus, led to the identification of small molecules, such as those that target spindle Kinesins, Aurora and Polo-like kinases. Unfortunately, these so-called second-generation of antimitotics, encompassing mitotic blockers and mitotic drivers, have failed in clinical trials. Our recent understanding regarding the mechanisms of cell death during a mitotic arrest pointed out apoptosis as the main variable, providing an opportunity to control the cell fates and influence the effectiveness of antimitotics. Here, we provide an overview on the second-generation of antimitotics, and discuss possible strategies that exploit SAC activity, mitotic slippage/exit and apoptosis induction, in order to improve the efficacy of anticancer strategies that target mitosis.
Collapse
Affiliation(s)
- Ana C Henriques
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal; INEB, Instituto Nacional de Engenharia Biomédica, Universidade Do Porto, Porto, Portugal
| | - Diana Ribeiro
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal; Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade Do Porto, Porto, Portugal
| | - Joel Pedrosa
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal
| | - Bruno Sarmento
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal; INEB, Instituto Nacional de Engenharia Biomédica, Universidade Do Porto, Porto, Portugal; i3S - Instituto de Investigação e Inovação Em Saúde, Universidade Do Porto, Porto, Portugal
| | - Patrícia M A Silva
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal
| | - Hassan Bousbaa
- CESPU, Instituto de Investigação e Formação Avançada Em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra PRD, Portugal; Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade Do Porto, Porto, Portugal.
| |
Collapse
|
14
|
Hu Y, Yagüe E, Zhao J, Wang L, Bai J, Yang Q, Pan T, Zhao H, Liu J, Zhang J. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett 2018; 423:47-59. [DOI: 10.1016/j.canlet.2018.02.036] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 02/18/2018] [Accepted: 02/22/2018] [Indexed: 02/07/2023]
|
15
|
Doğan A, Demirci S, Türkmen NB, Çağlayan AB, Aydın S, Telci D, Kılıç E, Şahin K, Orhan C, Tuzcu M, Ekici AID, Şahin F. Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice. Prostate 2016; 76:1454-63. [PMID: 27338565 DOI: 10.1002/pros.23229] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 06/14/2016] [Indexed: 11/06/2022]
Abstract
BACKGROUND Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest. METHOD In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity. RESULTS Results demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination decreased tumor formation and tumor volume steadily over the course of experiments. CONCLUSIONS Overall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454-1463, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Ayşegül Doğan
- Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey.
| | - Selami Demirci
- Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
| | - Neşe Başak Türkmen
- Department of Pharmaceutical Toxicology, Inonu University, Malatya, Turkey
| | - Ahmet Burak Çağlayan
- Faculty of Medicine, Department of Physiology, Istanbul Medipol University, Istanbul, Turkey
| | - Safa Aydın
- Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
| | - Dilek Telci
- Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
| | - Ertuğrul Kılıç
- Faculty of Medicine, Department of Physiology, Istanbul Medipol University, Istanbul, Turkey
| | - Kazım Şahin
- Faculty of Veterinary Medicine, Department of Animal Nutrition, Fırat University, Elazığ, Turkey
| | - Cemal Orhan
- Faculty of Veterinary Medicine, Department of Animal Nutrition, Fırat University, Elazığ, Turkey
| | - Mehmet Tuzcu
- Faculty of Science, Department of Biology, Fırat University, Elazığ, Turkey
| | | | - Fikrettin Şahin
- Faculty of Engineering and Architecture, Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
| |
Collapse
|
16
|
Cui J, Placzek WJ. PTBP1 modulation of MCL1 expression regulates cellular apoptosis induced by antitubulin chemotherapeutics. Cell Death Differ 2016; 23:1681-90. [PMID: 27367564 DOI: 10.1038/cdd.2016.60] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 04/30/2016] [Accepted: 05/30/2016] [Indexed: 01/01/2023] Open
Abstract
Myeloid cell leukemia sequence 1 (MCL1), an anti-apoptotic BCL2 family protein, is a key regulator of intrinsic apoptosis. Normal cells require strict control over MCL1 expression with aberrant MCL1 expression linked to the emergence of various diseases and chemoresistance. Previous studies have detailed how MCL1 expression is regulated by multiple mechanisms both transcriptionally and translationally. However, characterization of the post-transcriptional regulators of MCL1 mRNA is limited. Polypyrimidine tract binding protein 1 (PTBP1) is a known regulator of post-transcriptional gene expression that can control mRNA splicing, translation, stability and localization. Here we demonstrate that PTBP1 binds to MCL1 mRNA and that knockdown of PTBP1 upregulates MCL1 expression in cancer cells by stabilizing MCL1 mRNA and increasing MCL1 mRNA accumulation in cytoplasm. Further, we show that depletion of PTBP1 protects cancer cells from antitubulin agent-induced apoptosis in a MCL1-dependent manner. Taken together, our findings suggest that PTBP1 is a novel regulator of MCL1 mRNA by which it controls apoptotic response to antitubulin chemotherapeutics.
Collapse
Affiliation(s)
- J Cui
- Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - W J Placzek
- Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
17
|
Kroon J, Kooijman S, Cho NJ, Storm G, van der Pluijm G. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Trends Pharmacol Sci 2016; 37:451-462. [DOI: 10.1016/j.tips.2016.03.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 03/08/2016] [Accepted: 03/18/2016] [Indexed: 01/26/2023]
|
18
|
Wu DW, Wu TC, Chen CY, Lee H. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. Clin Cancer Res 2016; 22:5370-5382. [PMID: 27178741 DOI: 10.1158/1078-0432.ccr-15-2724] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Accepted: 05/08/2016] [Indexed: 11/16/2022]
Abstract
PURPOSE EGFR mutation as a biomarker has documented that EGFR-mutant patients will derive clinical benefit from tyrosine kinase inhibitor (TKI) treatment. Unfortunately, most patients show TKI resistance and tumor recurrence after therapy. Therefore, we expected that an adjuvant biomarker other than EGFR mutation is needed for predicting TKI resistance. EXPERIMENTAL DESIGN Molecular manipulations were performed to verify whether TKI resistance mediated by p21-activated kinase (PAK1) could be through increasing Mcl-1 protein stability via the PI3K/AKT/C/EBP-β/miR-145 cascade. Xenograft mouse models were used to confirm the mechanistic action of PAK1 on TKI resistance. Forty-six tumor tissues from patients with lung adenocarcinoma who received TKI therapy were collected to evaluate PAK1 and E-cadherin mRNA expressions by real-time PCR. The association of PAK1 and E-cadherin mRNA expressions with tumor response to TKI treatment and outcomes was evaluated. RESULTS We demonstrate that PAK1 confers TKI resistance in EGFR-mutant cells as well as in EGFR-wild-type cells. Mechanistically, the positive feedback loop of PAK1/PI3K/AKT/C/EBP-β/miR-145 cascades persistently activates the PI3K/AKT signaling pathway to protect Mcl-1 degradation by Fbw7, which results, in turn, in TKI resistance and cell invasion via epithelial-to-mesenchymal transition due to a decrease in E-cadherin expression. The mechanism underlying the cell model is further confirmed in xenograft tumors. Among patients, high-PAK1 or low-E-cadherin tumors more commonly exhibited an unfavorable response to TKI and poorer outcome compared with low-PAK1 or low-E-cadherin tumors. CONCLUSIONS The combination of TKI with AKT inhibitor might confer TKI sensitivity and in turn improve outcomes in patients with lung adenocarcinoma who harbored high PAK1 mRNA-expressing tumors. Clin Cancer Res; 22(21); 5370-82. ©2016 AACR.
Collapse
Affiliation(s)
- De-Wei Wu
- Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, ROC
| | - Tzu-Chin Wu
- Division of Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC
| | - Chih-Yi Chen
- Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC
| | - Huei Lee
- Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, ROC.
| |
Collapse
|
19
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 2015; 35 Suppl:S78-S103. [PMID: 25936818 PMCID: PMC4720504 DOI: 10.1016/j.semcancer.2015.03.001] [Citation(s) in RCA: 527] [Impact Index Per Article: 58.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Revised: 03/04/2015] [Accepted: 03/04/2015] [Indexed: 12/15/2022]
Abstract
Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
Collapse
Affiliation(s)
- Ramzi M Mohammad
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States; Interim translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
| | - Irfana Muqbil
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
| | - Leroy Lowe
- Getting to Know Cancer, Truro, Nova Scotia, Canada
| | - Clement Yedjou
- C-SET, [Jackson, #229] State University, Jackson, MS, United States
| | - Hsue-Yin Hsu
- Department of Life Sciences, Tzu-Chi University, Hualien, Taiwan
| | - Liang-Tzung Lin
- Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Markus David Siegelin
- Department of Pathology and Cell Biology, Columbia University, New York City, NY, United States
| | - Carmela Fimognari
- Dipartimento di Scienze per la Qualità della Vita Alma Mater Studiorum-Università di Bologna, Italy
| | - Nagi B Kumar
- Moffit Cancer Center, University of South Florida College of Medicine, Tampa, FL, United States
| | - Q Ping Dou
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States; Departments of Pharmacology and Pathology, Karmanos Cancer Institute, Detroit MI, United States
| | - Huanjie Yang
- The School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang, China
| | | | - Gian Luigi Russo
- Institute of Food Sciences National Research Council, Avellino, Italy
| | - Carmela Spagnuolo
- Institute of Food Sciences National Research Council, Avellino, Italy
| | - Swapan K Ray
- Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States
| | - Mrinmay Chakrabarti
- Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States
| | - James D Morre
- Mor-NuCo, Inc, Purdue Research Park, West Lafayette, IN, United States
| | - Helen M Coley
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom
| | - Kanya Honoki
- Department of Orthopedic Surgery, Nara Medical University, Kashihara, Japan
| | - Hiromasa Fujii
- Department of Orthopedic Surgery, Nara Medical University, Kashihara, Japan
| | - Alexandros G Georgakilas
- Department of Physics, School of Applied Mathematical and Physical Sciences, National Technical University of Athens, Zografou 15780, Athens, Greece
| | - Amedeo Amedei
- Department of Experimental and Clinical Medicine, university of florence, Italy
| | - Elena Niccolai
- Department of Experimental and Clinical Medicine, university of florence, Italy
| | - Amr Amin
- Department of Biology, College of Science, UAE University, United Arab Emirates; Faculty of Science, Cairo University, Egypt
| | - S Salman Ashraf
- Department of Chemistry, College of Science, UAE University, United Arab Emirates
| | - William G Helferich
- Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL, United States
| | - Xujuan Yang
- Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL, United States
| | - Chandra S Boosani
- Department of BioMedical Sciences, School of Medicine Creighton University, Omaha NE, United States
| | - Gunjan Guha
- School of Chemical and Bio Technology, SASTRA University, Thanjavur, India
| | - Dipita Bhakta
- School of Chemical and Bio Technology, SASTRA University, Thanjavur, India
| | | | - Katia Aquilano
- Department of Biology, University of Rome "Tor Vergata", Italy
| | - Sophie Chen
- Ovarian and Prostate Cancer Research Trust Laboratory, Guildford, Surrey, United Kingdom
| | - Sulma I Mohammed
- Department of Comparative Pathobiology and Purdue University Center for Cancer Research, Purdue, West Lafayette, IN, United States
| | - W Nicol Keith
- Institute of Cancer Sciences, University of Glasgow, Glasgow, Ireland
| | - Alan Bilsland
- Institute of Cancer Sciences, University of Glasgow, Glasgow, Ireland
| | - Dorota Halicka
- Department of Pathology, New York Medical College, Valhalla, NY, United States
| | - Somaira Nowsheen
- Mayo Graduate School, Mayo Medical School, Mayo Clinic Medical Scientist Training Program, Rochester, MN, United States
| | - Asfar S Azmi
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
| |
Collapse
|
20
|
Moselhy J, Srinivasan S, Ankem MK, Damodaran C. Natural Products That Target Cancer Stem Cells. Anticancer Res 2015; 35:5773-5788. [PMID: 26503998 PMCID: PMC7523548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The cancer stem cell model suggests that tumor initiation is governed by a small subset of distinct cells with stem-like character termed cancer stem cells (CSCs). CSCs possess properties of self-renewal and intrinsic survival mechanisms that contribute to resistance of tumors to most chemotherapeutic drugs. The failure to eradicate CSCs during the course of therapy is postulated to be the driving force for tumor recurrence and metastasis. Recent studies have focused on understanding the unique phenotypic properties of CSCs from various tumor types, as well as the signaling pathways that underlie self-renewal and drug resistance. Natural products (NPs) such as those derived from botanicals and food sources may modulate vital signaling pathways involved in the maintenance of CSC phenotype. The Wingless/Integrated (WNT), Hedgehog, Notch and PI3K/AKT/mTOR pathways have all been associated with quiescence and self-renewal of CSCs, as well as execution of CSC function including differentiation, multidrug resistance and metastasis. Recent studies evaluating NPs against CSC support the epidemiological evidence linking plant-based diets with reduced malignancy rates. This review covers the key aspects of NPs as modulators of CSC fate.
Collapse
Affiliation(s)
- Jim Moselhy
- Department of Urology, University of Louisville, Louisville, KY, U.S.A
| | | | - Murali K Ankem
- Department of Urology, University of Louisville, Louisville, KY, U.S.A
| | - Chendil Damodaran
- Department of Urology, University of Louisville, Louisville, KY, U.S.A.
| |
Collapse
|
21
|
Maji S, Samal SK, Pattanaik L, Panda S, Quinn BA, Das SK, Sarkar D, Pellecchia M, Fisher PB, Dash R. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 2015; 6:16623-37. [PMID: 26009874 PMCID: PMC4599294 DOI: 10.18632/oncotarget.3932] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Accepted: 04/30/2015] [Indexed: 11/25/2022] Open
Abstract
Oral and oropharyngeal cancers are the sixth most common cancers worldwide. Despite intensive investigation, oral squamous cell carcinomas (OSCC) represent a clinical challenge resulting in significant morbidity and mortality. Resistance to cell death is common in OSCC and is often mediated by the Bcl-2 family proteins. Among all anti-apoptotic Bcl-2 family members, Mcl-1 functions as a major survival factor, particularly in solid cancers. Despite the confirmed importance of Mcl-1 in several neoplasms, the role of Mcl-1 in OSCC survival has yet to be explored. In this study, we found that knocking down Mcl-1 sensitized OSCC cells to ABT-737, which binds to Bcl-2/Bcl-xL but not Mcl-1. We report for the first time that a BH3 mimetic, Sabutoclax, which functions as an inhibitor of all anti-apoptotic Bcl-2 proteins, induced cancer-specific cell death in an Mcl-1-dependent manner through both apoptosis and toxic mitophagy. In vivo studies demonstrated that Sabutoclax alone decreased tumor growth in a carcinogen-induced tongue OSCC mouse model. In a combination regimen, Sabutoclax and COX-2 inhibitor, Celecoxib, synergistically inhibited the growth of OSCC in vitro and also significantly reduced OSCC tumor growth in vivo. Overall, these results identify Mcl-1 as a therapeutic prospective target in OSCC.
Collapse
Affiliation(s)
- Santanu Maji
- Institute of Life Sciences, Bhubaneswar, Odisha, India
- Manipal University, Karnataka, India
| | - Sabindra K Samal
- Institute of Life Sciences, Bhubaneswar, Odisha, India
- Manipal University, Karnataka, India
| | | | - Swagatika Panda
- Department of Oral Pathology & Microbiology, Institute of Dental Sciences, ‘Siksha O Anusandhan’ University, Bhubaneswar, Odisha, India
| | - Bridget A. Quinn
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Swadesh K. Das
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Devanand Sarkar
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | | | - Paul B. Fisher
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
- VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Rupesh Dash
- Institute of Life Sciences, Bhubaneswar, Odisha, India
| |
Collapse
|
22
|
Pasqualini L, Bu H, Puhr M, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, Schweiger MR, Fuchsberger C, Klocker H. miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. Mol Endocrinol 2015; 29:1037-54. [PMID: 26052614 DOI: 10.1210/me.2014-1358] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
The normal prostate as well as early stages and advanced prostate cancer (PCa) require a functional androgen receptor (AR) for growth and survival. The recent discovery of microRNAs (miRNAs) as novel effector molecules of AR disclosed the existence of an intricate network between AR, miRNAs and downstream target genes. In this study DUCaP cells, characterized by high content of wild-type AR and robust AR transcriptional activity, were chosen as the main experimental model. By integrative analysis of chromatin immunoprecipitation-sequencing (ChIP-seq) and microarray expression profiling data, miRNAs putatively bound and significantly regulated by AR were identified. A direct AR regulation of miR-22, miR-29a, and miR-17-92 cluster along with their host genes was confirmed. Interestingly, endogenous levels of miR-22 and miR-29a were found to be reduced in PCa cells expressing AR. In primary tumor samples, miR-22 and miR-29a were less abundant in the cancerous tissue compared with the benign counterpart. This specific expression pattern was associated with a differential DNA methylation of the genomic AR binding sites. The identification of laminin gamma 1 (LAMC1) and myeloid cell leukemia 1 (MCL1) as direct targets of miR-22 and miR-29a, respectively, suggested a tumor-suppressive role of these miRNAs. Indeed, transfection of miRNA mimics in PCa cells induced apoptosis and diminished cell migration and viability. Collectively, these data provide additional information regarding the complex regulatory machinery that guides miRNAs activity in PCa, highlighting an important contribution of miRNAs in the AR signaling.
Collapse
Affiliation(s)
- Lorenza Pasqualini
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Huajie Bu
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Martin Puhr
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Narisu Narisu
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Johannes Rainer
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Bettina Schlick
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Georg Schäfer
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Mihaela Angelova
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Zlatko Trajanoski
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Stefan T Börno
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Michal R Schweiger
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Christian Fuchsberger
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| | - Helmut Klocker
- Department of Urology (L.P., H.B., M.P., B.S., G.S., H.K.), Division of Experimental Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Research Institute for Biomedical Aging Research (H.B.), University of Innsbruck, 6020 Innsbruck, Austria; Medical Genomics and Metabolic Genetics Branch (N.N.), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892; Biocenter Innsbruck (J.R.), Section for Molecular Pathophysiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; Center for Biomedicine (J.R., C.F.), EURAC Bolzano, 39100 Bolzano, Italy; Oncotyrol (B.S.), Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria; Department of Pathology (G.S.), Medical University of Innsbruck, 6020 Innsbruck, Austria; Biocenter Innsbruck (M.A., Z.T.), Division of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria; Max Planck Institute for Molecular Genetics (S.T.B., M.R.S.), 14195 Berlin, Germany; Cologne Center for Genomics (M.R.S.), University of Cologne, 50931 Cologne, Germany; and Department of Biostatistic (C.F.), University of Michigan, Ann Arbor, Michigan 48109
| |
Collapse
|
23
|
Quinn BA, Lee NA, Kegelman TP, Bhoopathi P, Emdad L, Das SK, Pellecchia M, Sarkar D, Fisher PB. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma. Adv Cancer Res 2015; 127:283-306. [PMID: 26093904 DOI: 10.1016/bs.acr.2015.04.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
With therapies that date back to the 1950s, and few newly approved treatments in the last 20 years, pancreatic cancer remains a significant challenge for the development of novel therapeutics. Current regimens have successfully extended patient survival, although they still lead to prognoses measured in months rather than years. The genetic diversity inherent in pancreatic tumors forms the roadblocks that must be overcome in future therapeutics. Recent insight into the genetic patterns found in tumor cells may provide clues leading to better understanding of the challenges hindering the development of treatments. Here, we review currently used drugs and established combination therapies that comprise the standard of care for a highly recalcitrant disease. Novel approaches can improve upon current therapies in a variety of ways. Enhancing specificity, such that growth inhibition and cytotoxic effects act preferentially on tumor cells, is one approach to advance treatments. This can be accomplished through the targeting of extracellular markers specific to cancer cells. Additionally, enlisting natural defenses and overcoming tumor-driven immune suppression could prove to be a useful tactic. Recent studies utilizing these approaches have yielded promising results and could contribute to an ongoing effort battling a particularly difficult cancer.
Collapse
Affiliation(s)
- Bridget A Quinn
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Nathaniel A Lee
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; Department of Surgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Timothy P Kegelman
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Praveen Bhoopathi
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Luni Emdad
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Swadesh K Das
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | | | - Devanand Sarkar
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Paul B Fisher
- Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
| |
Collapse
|
24
|
Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nat Commun 2014; 5:5637. [DOI: 10.1038/ncomms6637] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 10/21/2014] [Indexed: 12/19/2022] Open
|
25
|
Cancer subclonal genetic architecture as a key to personalized medicine. Neoplasia 2014; 15:1410-20. [PMID: 24403863 DOI: 10.1593/neo.131972] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 12/03/2013] [Accepted: 12/03/2013] [Indexed: 02/08/2023] Open
Abstract
The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s) driving growth and progression of a patient's tumor is imperative. Although molecular subtyping is important for planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implications for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient's cancer and how this will impact on the selection of the most efficacious therapy remain a topic of intense interest.
Collapse
|
26
|
Mohana-Kumaran N, Hill DS, Allen JD, Haass NK. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res 2014; 27:525-39. [PMID: 24655414 DOI: 10.1111/pcmr.12242] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Accepted: 03/17/2014] [Indexed: 01/02/2023]
Abstract
Melanoma drug resistance is often attributed to abrogation of the intrinsic apoptosis pathway. Targeting regulators of apoptosis is thus considered a promising approach to sensitizing melanomas to treatment. The development of small-molecule inhibitors that mimic natural antagonists of either antiapoptotic members of the BCL-2 family or the inhibitor of apoptosis proteins (IAPs), known as BH3- or SMAC-mimetics, respectively, are helping us to understand the mechanisms behind apoptotic resistance. Studies using BH3-mimetics indicate that the antiapoptotic BCL-2 protein MCL-1 and its antagonist NOXA are particularly important regulators of BCL-2 family signaling, while SMAC-mimetic studies show that both XIAP and the cIAPs must be targeted to effectively induce apoptosis of cancer cells. Although most solid tumors, including melanoma, are insensitive to these mimetic drugs as single agents, combinations with other therapeutics have yielded promising results, and tests combining them with BRAF-inhibitors, which have already revolutionized melanoma treatment, are a clear priority.
Collapse
Affiliation(s)
- Nethia Mohana-Kumaran
- The Centenary Institute, Newtown, NSW, Australia; School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia
| | | | | | | |
Collapse
|
27
|
Roy MJ, Vom A, Czabotar PE, Lessene G. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol 2014; 171:1973-87. [PMID: 24117105 PMCID: PMC3976616 DOI: 10.1111/bph.12431] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Revised: 09/13/2013] [Accepted: 09/18/2013] [Indexed: 12/27/2022] Open
Abstract
The principal biological role of mitochondria is to supply energy to cells; although intriguingly, evolution has bestowed another essential function upon these cellular organelles: under physiological stress, mitochondria become the cornerstone of apoptotic cell death. Specifically, mitochondrial outer membrane permeabilization (MOMP) allows cell death factors such as cytochrome c to be released into the cytoplasm, thus inducing caspase activation and the eventual destruction of essential cellular components. Proteins of the B-cell lymphoma 2 (BCL-2) family control the tightly regulated pathway that causes MOMP. The equilibrium between pro-survival and pro-apoptotic members of the BCL-2 family dictates the fate of cells, the homeostasis of organs and, by extension, the health of whole organisms. Dysregulation of this equilibrium is involved in a large number of diseases such as cancer, autoimmunity and neurodegenerative conditions. Modulating the activity of the BCL-2 family of proteins with small molecules or peptides is an attractive but challenging therapeutic goal. This review highlights the latest developments in this field and provides evidence that this strategy is likely to have a positive effect on the treatment of still poorly addressed medical conditions.
Collapse
Affiliation(s)
- M J Roy
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - A Vom
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - P E Czabotar
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - G Lessene
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
- Department of Pharmacology and Therapeutics, The University of MelbourneMelbourne, Vic, Australia
| |
Collapse
|
28
|
Abstract
Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2, BCL-XL, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.
Collapse
|
29
|
Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 2013; 15:568-78. [PMID: 23633928 DOI: 10.1593/neo.13230] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 02/26/2013] [Accepted: 03/04/2013] [Indexed: 11/18/2022]
Abstract
Owing to the high levels of antiapoptotic B-cell lymphoma 2 (BCL-2) family members observed in several cancers, there has been a major effort to develop inhibitors of the BCL2-family as chemotherapeutic agents. Of the different members in the BCL-2 family, myeloid cell leukemia sequence 1 (MCL-1) is commonly amplified in human tumors and is associated with their relapse and chemoresistance. As a result, specific inhibitors of MCL-1 are being designed to treat resistant tumors. However, there is increasing evidence for other nonapoptotic roles of the BCL-2 family, ranging from ionic homeostasis and autophagy to the regulation of fission-fusion dynamics in subcellular organelles, including the endoplasmic reticulum and mitochondria. In this study, we characterize the specificity of two novel putative MCL-1 inhibitors, BI97C1 (Sabutoclax) and BI112D1, in inducing apoptosis in a BAX/BAK-dependent manner and in an MCL-1-dependent system. In addition to their being proapoptotic, these inhibitors also cause enhanced mitochondrial fragmentation that accompanies a time-dependent loss of optic atrophy 1 (OPA1), suggesting an impairment of mitochondrial fusion. This mitochondrial fragmentation occurs independently of dynamin-related protein 1 (DRP1)-mediated fission activity and, unlike most apoptotic stimuli, occurs upstream of and/or independent of BAX, BAK, and other BH3-only proteins. Furthermore, this mitochondrial fragmentation occurred rapidly and preceded other hallmarks of apoptosis, including the loss in mitochondrial membrane potential and the release of cytochrome c. Although such mitochondrial fragmentation did not deplete total cellular adenosine triphosphate (ATP) or alter other mitochondrial complexes, there was significant accumulation of reactive oxygen species.
Collapse
|
30
|
Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One 2013; 8:e78570. [PMID: 24223823 PMCID: PMC3817219 DOI: 10.1371/journal.pone.0078570] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Accepted: 09/13/2013] [Indexed: 12/15/2022] Open
Abstract
Background and purpose Metastatic melanoma remains one of the most invasive and highly drug resistant cancers. The over expression of anti-apoptotic protein Mcl-1 has been associated with inferior survival, poor prognosis and chemoresistance of malignant melanoma. A BH3 mimetic, ABT-737, has demonstrated efficacy in several forms of cancers. However, the efficacy of ABT-737 depends on Mcl-1. Because the over expression of Mcl-1 is frequently observed in melanoma, specifically targeting of Mcl-1 may overcome the resistance of ABT-737. In this study, we investigated the effects of Maritoclax, a novel Mcl-1-selective inhibitor, alone and in combination with ABT-737, on the survival of human melanoma cells. Experimental approach For cell viability assessment we performed MTT assay. Apoptosis was determined using western blot and flow cytometric analysis. Key results The treatment of Maritoclax reduced the cell viability of melanoma cells with an IC50 of between 2.2–5.0 µM. Further, treatment of melanoma cells with Maritoclax showed significant decrease in Mcl-1 expression. We found that Maritoclax was able to induce apoptosis in melanoma cells in a caspase-dependent manner. Moreover, Maritoclax induced Mcl-1 degradation via the proteasome system, which was associated with its pro-apoptotic activity. We also found that Maritoclax treatment increased mitochondrial translocation of Bim and Bmf. Importantly, Maritoclax markedly enhanced the efficacy of ABT-737 against melanoma cells in both two- and three-dimensional spheroids. Conclusions and implications Taken together, these results suggest that targeting of Mcl-1 by Maritoclax may represent a new therapeutic strategy for melanoma treatment that warrants further investigation as a single therapy or in combination with other agents such as Bcl-2 inhibitors.
Collapse
Affiliation(s)
- Manoj K. Pandey
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
| | - Krishne Gowda
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
| | - Kenichiro Doi
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
| | - Arun K. Sharma
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
| | - Hong-Gang Wang
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
- * E-mail: (SA); (HGW)
| | - Shantu Amin
- Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, United States of America
- * E-mail: (SA); (HGW)
| |
Collapse
|
31
|
A reciprocal role of prostate cancer on stromal DNA damage. Oncogene 2013; 33:4924-31. [PMID: 24141771 PMCID: PMC4121379 DOI: 10.1038/onc.2013.431] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 09/02/2013] [Accepted: 09/05/2013] [Indexed: 12/16/2022]
Abstract
DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the absence of somatic mutations in CAF, epigenetic changes dictate how stromal coevolution is mediated in tumors. Seventy percent of prostate cancer patients lose expression of transforming growth factor-beta type II receptor (TGFBR2) in the stromal compartment (n=77, P-value=0.0001), similar to the rate of glutathione S-transferase P1 (GSTP1) silencing. Xenografting of human prostate cancer epithelia, LNCaP, resulted in the epigenetic Tgfbr2 silencing of host mouse prostatic fibroblasts. Stromal Tgfbr2 promoter hypermethylation, initiated by LNCaP cells, was found to be dependent on interleukin 6 expression, based on neutralizing antibody studies. We further found that pharmacologic and transgenic knockout of TGF-β responsiveness in prostatic fibroblasts induced Gstp1 promoter methylation. It is known that TGF-β promotes DNA stability, however, the mechanism is not well understood. Both prostatic human CAF and mouse transgenic knockout of Tgbr2 had elevated DNA methyltransferase I (DNMT1) activity and histone H3 lysine 9 trimethylation (H3K9me3) to suggest greater promoter methylation. Interestingly, the conditional knockout of Tgfbr2 in mouse prostatic fibroblasts, in modeling epigenetic silencing of Tgfbr2, had greater epigenetic gene silencing of multiple DNA damage repair and oxidative stress response genes, based on promoter methylation array analysis. Homologous gene silencing was validated by reverse transcriptase (RT)-PCR in mouse and human prostatic CAF. Not surprisingly, DNA damage repair gene silencing in the prostatic stromal cells corresponded with the presence of DNA damage. Restoring the expression of the epigenetically silenced genes in wild-type fibroblasts with radiation-induced DNA damage reduced tumor progression. Tumor progression was inhibited even when epigenetic silencing was reversed in the Tgfbr2-knockout prostatic fibroblasts. Taken together, fibroblastic epigenetic changes causative of DNA damage, initiated by association with cancer epithelia, is a dominant mediator of tumor progression over TGF-β responsiveness.
Collapse
|
32
|
Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia 2013; 15:1172-83. [PMID: 24204196 PMCID: PMC3819633 DOI: 10.1593/neo.13986] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Revised: 08/07/2013] [Accepted: 08/09/2013] [Indexed: 12/12/2022]
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is activated in most advanced prostate cancers, yet so far treatments with PI3K inhibitors have been at best tumorostatic in preclinical cancer models and do not show significant antitumor efficacy in clinical trials. Results from tissue culture experiments in prostate cancer cells suggest that PI3K inhibitors should be combined with other cytotoxic agents; however, the general toxicity of such combinations prevents translating these experimental data into preclinical and clinical models. We investigated the emerging concept of tumor-targeted synthetic lethality in prostate cancer cells by using the pan-PI3K inhibitor ZSTK474 and the immunotoxin J591PE, a protein chimera between the single-chain variable fragment of the monoclonal antibody J591 against the prostate-specific membrane antigen (PSMA) and the truncated form of the Pseudomonas aeruginosa exotoxin A (PE38QQR). The combination of ZSTK474 and J591PE increased apoptosis within 6 hours and cell death (monitored at 24-48 hours) in the PSMA-expressing cells LNCaP, C4-2, and C4-2Luc but not in control cells that do not express PSMA (PC3 and BT549 cells). Mechanistic analysis suggested that induction of apoptosis requires Bcl-2-associated death promoter (BAD) dephosphorylation and decreased expression of myeloid leukemia cell differentiation protein 1 (MCL-1). A single injection of ZSTK474 and J591PE into engrafted prostate cancer C4-2Luc cells led to consistent and stable reduction of luminescence within 6 days. These results suggest that the combination of a PI3K inhibitor and a PSMA-targeted protein synthesis inhibitor toxin represents a promising novel strategy for advanced prostate cancer therapy that should be further investigated.
Collapse
Affiliation(s)
- Daniele Baiz
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Sazzad Hassan
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Young A Choi
- Department of Neurosurgery and Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC
| | - Anabel Flores
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Yelena Karpova
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Dana Yancey
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Ashok Pullikuth
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Guangchao Sui
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| | - Michel Sadelain
- Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Waldemar Debinski
- Department of Neurosurgery and Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC
| | - George Kulik
- Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC
| |
Collapse
|
33
|
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia 2013; 14:1278-89. [PMID: 23308059 DOI: 10.1593/neo.122096] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Revised: 12/11/2012] [Accepted: 12/11/2012] [Indexed: 12/14/2022] Open
Abstract
Improvements in technology and resources are helping to advance our understanding of cancer-initiating events as well as factors involved with tumor progression, adaptation, and evasion of therapy. Tumors are well known to contain diverse cell populations and intratumor heterogeneity affords neoplasms with a diverse set of biologic characteristics that can be used to evolve and adapt. Intratumor heterogeneity has emerged as a major hindrance to improving cancer patient care. Polygenic cancer drug resistance necessitates reconsidering drug designs to include polypharmacology in pursuit of novel combinatorial agents having multitarget activity to overcome the diverse and compensatory signaling pathways in which cancer cells use to survive and evade therapy. Advances will require integration of different biomarkers such as genomics and imaging to provide for more adequate elucidation of the spatially varying location, type, and extent of diverse intratumor signaling molecules to provide for a rationale-based personalized cancer medicine strategy.
Collapse
|
34
|
Abstract
Important inroads have been made in the understanding and treatment of metastatic prostate cancer in recent years. However, the need for agents targeting novel pathways remains ever present. One such area with promise is through apoptosis or programmed cell death. Many perturbations within the apoptotic process have been associated with treatment resistance and progression in castration-resistant prostate cancer; thus, therapeutic potential exists with agents that can restore an effective apoptotic response to cellular stressors. This article focuses on agents in clinical development targeting apoptosis through the intrinsic and extrinsic pathways. We review the current status of agents that intervene at the Bcl2 checkpoints, humanized antibodies to death receptors, agents that target the inhibitors of apoptosis proteins, mimetics of small mitochondria-derived activator of caspases, and antisense therapies targeting cytoprotective chaperones. Although single-agent activity has been demonstrated with some of these agents, the clinical development path forward will see them coupled with standard hormonal therapy and chemotherapy. OGX-011 (custirsen), which inhibits expression of the cytoprotective chaperone protein clusterin, is the most mature of these agents and is being tested in combination with chemotherapy in phase III clinical trials for castration-resistant prostate cancer, and results are eagerly awaited.
Collapse
|
35
|
IL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regeneration. PLoS One 2013; 8:e66268. [PMID: 23825534 PMCID: PMC3692501 DOI: 10.1371/journal.pone.0066268] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 05/02/2013] [Indexed: 12/21/2022] Open
Abstract
Aims To investigate the role and the regulation of the long variant of myeloid cell leukemia-1 protein (Mcl-1L) during liver regeneration. Background Liver regeneration is an important phenomenon after liver injury. The rat partial hepatectomy (PH) model was used to characterize liver regeneration and Mcl-1L expression after PH. Methods Male Wistar rats were subjected to 70% PH. The expression of mcl-1L mRNA was determined by quantitative RT-PCR, and protein levels were analyzed by Western blot analysis and immunohistochemistry during liver regeneration. Functional evaluations of Mcl-1L were tested using chemical inhibition (flavopiridol), genetic inhibition (siRNA) of Mcl-1L production, and by assaying for annexin V levels and DNA ladder formation. Serum IL-6 levels were determined by enzyme immunoassays; signal transduction of IL-6-regulated Mcl-1L expression was verified by chemical inhibitors and decoy double-stranded oligodeoxynucleotides. Results High levels of Mcl-1L were observed in remnant tissue at 4 h after PH. Administration of flavopiridol decreased Mcl-1L accumulation and also inhibited liver regeneration. IL-6 administration promoted the accumulation of Mcl-1L in rat hepatocytes, an effect that was impaired by siRNA treatments that reduced Mcl-1L production. Chemical inhibition and decoy oligonucleotide competition demonstrated that IL-6-induced Mcl-1L production required signaling mediated by JAK kinase, phosphoinositide 3-kinase (PI3K), and cAMP response-element-binding (CREB) proteins. Conclusion Mcl-1L is an anti-apoptotic protein induced during liver regeneration after PH in rats. The expression of Mcl-1L is induced by IL-6 through the JAK/PI3K/Akt/CREB signaling pathway. Chemotherapy drugs that depend on Mcl-1L- or IL-6-related signaling should be considered carefully before use in patients undergoing hepatectomy for malignant tumor resection.
Collapse
|
36
|
Current World Literature. Curr Opin Urol 2013. [DOI: 10.1097/mou.0b013e3283605159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer 2013; 2013:920612. [PMID: 23738079 PMCID: PMC3657461 DOI: 10.1155/2013/920612] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 03/25/2013] [Accepted: 03/28/2013] [Indexed: 01/28/2023] Open
Abstract
Prostate cancer (PCa) is one of the most common malignancies found in males. The development of PCa involves several mutations in prostate epithelial cells, usually linked to developmental changes, such as enhanced resistance to apoptotic death, constitutive proliferation, and, in some cases, to differentiation into an androgen deprivation-resistant phenotype, leading to the appearance of castration-resistant PCa (CRPCa), which leads to a poor prognosis in patients. In this review, we summarize recent findings concerning the main deregulations into signaling pathways that will lead to the development of PCa and/or CRPCa. Key mutations in some pathway molecules are often linked to a higher prevalence of PCa, by directly affecting the respective cascade and, in some cases, by deregulating a cross-talk node or junction along the pathways. We also discuss the possible environmental and nonenvironmental inducers for these mutations, as well as the potential therapeutic strategies targeting these signaling pathways. A better understanding of how some risk factors induce deregulation of these signaling pathways, as well as how these deregulated pathways affect the development of PCa and CRPCa, will further help in the development of new treatments and prevention strategies for this disease.
Collapse
|